Tandem Diabetes Care Inc at UBS Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. Thanks for joining us for our next session here at the UBS Virtual Global Healthcare Conference. I am Matt Taylor, UBS' U.S. medical supplies and devices analyst. And I'm really pleased to be joined by management from Tandem Diabetes. We have today on the line, John Sheridan, who's the President and CEO; and then we also have Leigh Vosseller, the EVP and CFO of the company.
So just as a point of orientation for this session, I'm going to be doing about a 40-minute moderated Q&A. If you have any questions, you can send them to me on e-mail or through the conference app, but we'll get started with John and Leigh here with a high-level question.
Tandem has had a lot of momentum with its products over the last couple of years, but especially with this new product launch that I think the diabetes community is very excited about Control-IQ. And that was evident in your trends in early Q1 pre-COVID. And so I was hoping that we could start by
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
